|
Post by tomtabb on Nov 1, 2018 21:10:37 GMT -5
This also bothered me a little: "Another very exciting development in the area of Tyvaso is our PR end program with the European company MedSpray and these guys are the leaders in a field of nano -- Nanosphere-based liquid powder deposition and -- with a device that requires no battery or electronic operation at all, we're able to have a deposition of this liquid powder that matches that that you get this Tyvaso. So this study is entering Phase 1. Actually, I believe the first patients are being randomized into Phase 1 in this quarter and then we will have the commercial -- final commercial product form delivered to us around the third quarter of next year and then move right into a kind of a rapid Phase II, Phase III study at the -- at the end of ( 2019 ) and then into 2019 and into 2020." What is a "PR end program"? I googled and could find the company and its products -- www.medspray.nl/tp-inhalers.html-- but couldn't find anything about any deals with UTHR. I couldn't find anything in SEC filings or in clinicaltrials either. Yet UTHR will receive the "final commercial product" in the 3rd quarter of next year"? Has there been any discussion of when UTHR will move forward with tre-t?
|
|